ADMA Biologics, Inc.
ADMA
$17.10
-$0.20-1.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 121.98M | 114.80M | 117.55M | 119.84M | 107.19M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 121.98M | 114.80M | 117.55M | 119.84M | 107.19M |
| Cost of Revenue | 54.76M | 53.71M | 54.22M | 60.18M | 49.74M |
| Gross Profit | 67.23M | 61.10M | 63.33M | 59.66M | 57.45M |
| SG&A Expenses | 23.37M | 25.37M | 24.59M | 19.58M | 17.55M |
| Depreciation & Amortization | 32.00K | 25.00K | 25.00K | 28.00K | 142.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 79.19M | 79.92M | 79.23M | 80.20M | 67.99M |
| Operating Income | 42.80M | 34.88M | 38.32M | 39.64M | 39.20M |
| Income Before Tax | 40.10M | 33.45M | 34.71M | 36.75M | 35.85M |
| Income Tax Expenses | 5.88M | 6.55M | -77.18M | 840.00K | 3.79M |
| Earnings from Continuing Operations | 34.22M | 26.90M | 111.90M | 35.91M | 32.06M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 34.22M | 26.90M | 111.90M | 35.91M | 32.06M |
| EBIT | 42.80M | 34.88M | 38.32M | 39.64M | 39.20M |
| EBITDA | 44.86M | 36.85M | 40.27M | 41.58M | 41.25M |
| EPS Basic | 0.14 | 0.11 | 0.47 | 0.15 | 0.14 |
| Normalized Basic EPS | 0.11 | 0.09 | 0.10 | 0.10 | 0.10 |
| EPS Diluted | 0.14 | 0.11 | 0.46 | 0.15 | 0.13 |
| Normalized Diluted EPS | 0.10 | 0.09 | 0.09 | 0.09 | 0.09 |
| Average Basic Shares Outstanding | 241.49M | 237.78M | 236.43M | 234.57M | 232.42M |
| Average Diluted Shares Outstanding | 248.61M | 244.68M | 245.90M | 244.80M | 242.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |